


LISTING OF THE CLAIMS

1. An acylhydroxamic acid derivative, selected from the group consisting of
 (a) compounds of the formula:



wherein

the carbon atom designated * constitutes a center of chirality,

R^4 is hydrogen or $-(C=O)-R^{12}$;

each of R^1 and R^{12} , independently of each other, is alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridyl methyl, pyridyl, imidazolyl, imidazolyl methyl, or

$CHR^*(CH_2)_nNR^*R^0$

wherein R^* and R^0 , independently of the other, are hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridylmethyl, pyridyl, imidazolyl or imidazolylmethyl, and $n = 0, 1, 2$;

R^5 is $C=O$, CH_2 , CH_2-CO- , or SO_2 ;

each of R^6 and R^7 , independently of the other, is nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxyl, carboxyl, hydroxyl, amino, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 8 carbon atoms, halo, bicycloalkyl of up to 18 carbon atoms, tricycloalkoxy of up to 18 carbon atoms, 1-indanyloxy, 2-indanyloxy, C_4-C_8 -cycloalkylidenemethyl, or C_3-C_{10} -alkylidenemethyl;


each of R^8 , R^9 , R^{10} , and R^{11} independently of the others, is

- (i) hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxyl, carboxyl, hydroxyl,

- amino, alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halo, or
- (ii) one of R^8 , R^9 , R^{10} , and R^{11} is acylamino comprising a lower alkyl, and the remaining of R^8 , R^9 , R^{10} , and R^{11} are hydrogen, or
- (iii) hydrogen if R^8 and R^9 taken together are benzo, quinoline, quinoxaline, benzimidazole, benzodioxole, 2-hydroxybenzimidazole, methylenedioxy, dialkoxy, or dialkyl, or
- (iv) hydrogen if R^{10} and R^{11} , taken together are benzo, quinoline, quinoxaline, benzimidazole, benzodioxole, 2-hydroxybenzimidazole, methylenedioxy, dialkoxy, or dialkyl, or
- (v) hydrogen if R^9 and R^{10} taken together are benzo; and
- (b) The acid addition salts of said compounds which contain a nitrogen atom capable of being protonated.

Claims 2-4. Cancelled

5. An acylhydroxamic acid derivative according to claim 1 wherein said compound has the formula:



in which

the carbon atom designated * constitutes a center of chirality;

R^4 is hydrogen or $-(C=O)-R^{12}$, where

each of R¹ and R¹², independently of each other, is alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridyl, pyridyl methyl, imidazolyl, imidazolymethyl, or CHR^{*}(CH₂)_nNR^{*}R⁰

wherein R^{*} and R⁰, independently of the other, are hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridylmethyl, pyridyl, imidazolyl or imidazolymethyl, and n = 0, 1, 2;

R⁵ is C=O or CH₂;

each of R⁶ and R⁷, independently of the other is alkoxy of 1 to 8 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms.; C₄-C₆-cycloalkylidenem ethyl, C₂-C₁₀alkylidenemethyl, C₆-C₁₈-bicycloalkoxy, C₆-C₁₈-tricycloalkoxy, 1-indanyloxy, or

2-indanyloxy; and

each of R⁸, R⁹, R¹⁰, and R¹¹, independently of the others, is hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, halo, carbamoyl, acetoxyl, carboxyl, hydroxyl, amino, alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, and alkoxy of 1 to 10 carbon atoms.

Claims 6-18. Cancelled

19. A pharmaceutical composition comprising a quantity of an acylhydroxamic acid derivative according to claim 1, which derivative is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof, sufficient upon administration in a single or multiple dose regimen to reduce or inhibit levels of TNF α or in a mammal in combination with a carrier.

20. A pharmaceutical composition comprising a quantity of an acylhydroxamic acid derivative according to claim 1, which derivative is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof, sufficient upon administration in a single or multiple dose regimen to inhibit undesirable levels of at least one of matrix metalloproteinases and PDE 4 in a mammal in combination with a carrier.

21. A method of inhibiting undesirable levels of TNF α in a mammal which comprises administering thereto an effective amount of an acylhydroxamic acid derivative according to claim 1, which derivative is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

22. A method of inhibiting undesirable levels of matrix metalloproteinases in a mammal which comprises administering thereto an effective amount of an acylhydroxamic acid derivative according to claim 1, which derivative is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

23. A method of treating in a mammal a disease selected from the group consisting of inflammatory disease and autoimmune disease, which comprises administering thereto an effective amount of a compound according to claim 1, which compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

24. A method according to claim 23 wherein the disease is at least one member selected from the group of arthritis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, aphthous ulcers, cachexia, graft versus host disease, asthma, COPD, psoriasis, atopic dermatitis, Lupus, adult respiratory distress syndrome, and acquired immune deficiency syndrome.

25. A method of treating cancer in a mammal which comprises administering thereto an effective amount of a compound according to claim 1, which compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

26. A method of treating undesirable angiogenesis in a mammal which comprises administering thereto an effective amount of a compound according to claim 1, which compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

27. A method of inhibiting phosphodiesterases type IV or PDE 4 in a mammal which comprises administering thereto an effective amount of an acylhydroxamic acid

derivative according to claim 1, which derivative is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

Claims 28-29. Cancelled.

30. A pharmaceutical composition comprising a quantity of an acylhydroxamic acid derivative according to claim 5, which derivative is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof, sufficient upon administration in a single or multiple dose regimen to reduce or inhibit levels of TNF α in a mammal in combination with a carrier.

31. A pharmaceutical composition comprising a quantity of an acylhydroxamic acid derivative according to claim 5, which derivative is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof, sufficient upon administration in a single or multiple dose regimen to inhibit undesirable levels of matrix metalloproteinases or PDE 4 in a mammal in combination with a carrier.

32. A method of reducing or inhibiting undesirable levels of TNF α in a mammal which comprises administering thereto an effective amount of an acylhydroxamic acid derivative according to claim 5, which derivative is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

33. A method of inhibiting undesirable levels of matrix metalloproteinases in a mammal which comprises administering thereto an effective amount of an acylhydroxamic acid derivative according to claim 5, which derivative is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

34. A method of treating in a mammal a disease selected from the group consisting of inflammatory disease and autoimmune disease, which comprises administering thereto an effective amount of a compound according to claim 5, which compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

35. A method according to claim 34, wherein the disease is at least one member selected from the group consisting of arthritis, rheumatoid arthritis, inflammatory bowel

disease, Crohn's disease, aphthous ulcers, cachexia, graft versus host disease, asthma, COPD, psoriasis, stopic dermatitis, Lupus, adult respiratory distress syndrome, and acquired immune deficiency syndrome

36. A method of treating cancer in a mammal which comprises administering thereto an effective amount of a compound according to claim 5, which compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

37. A method of treating undesirable angiogenesis in a mammal which comprises administering thereto an effective amount of a compound according to claim 5, which compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

38. A method of inhibiting undesirable levels of phosphodiesterase type IV in a mammal which comprises administering thereto an effective amount of an acylhydroxamic acid derivative according to claim 5, which derivative is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

39. A method of treating dermal diseases in a mammal which comprises administering thereto an effective amount of an acylhydroxamic acid derivative according to claim 5, which derivative is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

Claim 40. Cancelled.